Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.69 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.69 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.69 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.69 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.69 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.69 |
| ▸ | FABP2 | P12104 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867575 | 1.00 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL11851177 | 1.00 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| Tetraethylene Glycol SCHEMBL8877385 | 0.88 | AKR1C3 (0.56) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL2357849 | 0.85 | NPSR1 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL11836569 | 0.85 | NPSR1 (0.54) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL11836571 | 0.83 | PTGS1 (0.49) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL10705388 | 0.83 | MAOB (0.53) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| SCHEMBL11831008 | 0.83 | NPSR1 (0.51) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| Flurbiprofen SCHEMBL10029029 | 0.82 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 | |
| Tarenflurbil SCHEMBL26131 | 0.82 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603548-A4 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS INC (US) | 2007-10-10 | — | — | EP | claimed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | claimed |
| EP-1603548-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004071431-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-4209638-A | RESOLUTION OF ENANTIOMORPHS | THE BOOTS COMPANY LIMITED (GB) | 1980-06-24 | — | — | US | claimed |
| US-3973037-A | Hydratropic acid derivatives in the treatment of non-inflammatory allergic reactions | THE UPJOHN COMPANY (US) | 1976-08-03 | — | — | US | claimed |
| CN-111741944-A | Anticancer compounds | 悉尼大学 | 2020-10-02 | — | — | CN | disclosed |
| CN-103415286-A | Compounds and methods for treating pain | AKRON MOLECULES GMBH | 2013-11-27 | — | — | CN | disclosed |
| US-8512687-B2 | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides | NOVAGALI PHARMA SA (FR) | 2013-08-20 | — | — | US | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20110021443-A1 | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES | NOVAGALI PHARMA SA (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2016936-B1 | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides | NOVAGALI PHARMA SA (FR) | 2010-09-15 | — | — | EP | disclosed |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | WARATAH PHARMACEUTICALS INC. (CA) | 2010-07-08 | — | — | US | disclosed |
| EP-0237495-A2 | Halogenides of the ester of 2,N,N,N-dimethyl-alkyl-amino-ethanol with substituted acetic acid and pharmaceutical compositions having antiinflammatory and antiseptic activities containing same | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1987-09-16 | — | — | EP | disclosed |
| US-4542233-A | Process for preparing biaryl compounds via coupling of an arylamine with an arene | BIASCHIM S.P.A. (IT) | 1985-09-17 | — | — | US | disclosed |
| US-4501727-A | Therapeutic agent | THE BOOTS COMPANY PLC (GB) | 1985-02-26 | — | — | US | disclosed |
| EP-0100120-A1 | Improvement in the process for preparing biaryl compounds via coupling of an arylamine with an arene | Nobel Chemicals AB (SE) | 1984-02-08 | — | — | EP | disclosed |
| US-4391814-A | Derivatives of antiphlogistically effective carboxylic acids, their preparation and medicinal use | SCHERING AKTIENGESELLSCHAFT (DE) | 1983-07-05 | — | — | US | disclosed |
| US-4053639-A | 2-(2,2' OR 2,2'-FLUORO OR DIFLUORO-4-BIPHENYLYL)PROPAN-1-OL; ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | THE BOOTS COMPANY LIMITED (EN) | 1977-10-11 | — | — | US | disclosed |
| US-3973037-A | Hydratropic acid derivatives in the treatment of non-inflammatory allergic reactions | THE UPJOHN COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021443-A1 | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES | NFKBIA, RELA, TNF | AKR1C3 2646/4885AKR1C2 2318/4885PTGS2 23/4885 |
| US-20100173960-A1 | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases | HTT, APP, PSEN2 | AKR1C3 1310/4885AKR1C2 1392/4885PTGS2 23/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | AKR1C3 160/4885AKR1C2 446/4885PTGS2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.